Aspirin enhances the clinical efficacy of anti-tuberculosis therapy in pulmonary tuberculosis in patients with type 2 diabetes mellitus

References

• World Health Organization. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• Critchley JA, Restrepo BI, Ronacher K, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: Part 1: epidemiology and clinical management. Chest. 2017;152(1):165–173.
   PubMed Web of Science ®Google Scholar
• Hodgson K, Morris J, Bridson T, et al. Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 2015;144(2):171–185.
   PubMed Web of Science ®Google Scholar
• Lin Y, Yuan Y, Zhao X, et al. The change in blood glucose levels in tuberculosis patients before and during anti-tuberculosis treatment in China. Glob Health Action. 2017;10(1):1289737.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Tang T, Golub JE, et al. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80(4):634–639.
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 1971;231(25):232–235.
   PubMedGoogle Scholar
• Patrignani P, Patrono C. Aspirin, platelet inhibition and cancer prevention. Platelets. 2018 ;29(8):779–785.
   PubMed Web of Science ®Google Scholar
• Ogundeji AO, Pohl CH, Sebolai OM. Repurposing of aspirin and ibuprofen as candidate anti-cryptococcus drugs. Antimicrob Agents Chemother. 2016;60(8):4799–4808.
   PubMed Web of Science ®Google Scholar
• Richman IB, Owens DK. Aspirin for primary prevention. Med Clin North Am. 2017;101(4):713–724.
   PubMed Web of Science ®Google Scholar
• Byrne ST, Denkin SM, Zhang Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J Antimicrob Chemother. 2007;59(2):313–316.
   PubMed Web of Science ®Google Scholar
• Vilaplana C, Marzo E, Tapia G, et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis. 2013;208(2):199–202.
   PubMed Web of Science ®Google Scholar
• Laszlo A. Sputum examination for tuberculosis by direct microscopy in low income countries. Paris, France: IUATLD Technical Guide International Union against Tuberculosis and Lung Disease; 2000.
   Google Scholar
• Lomtadze N, Aspindzelashvili R, Janjgava M, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis. 2009;13(1):68–73.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33(Suppl 1):S62–S69.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Treatment of tuberculosis: guidelines. Geneva, Switzerland: World Health Organization; 2010.
   Google Scholar
• World Health Organization. Resolution WHA67/11: global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization: Geneva, Switzerland; 2014.
   Google Scholar
• Lee PH, Fu H, Lai TC, et al. Glycemic control and the risk of tuberculosis: a cohort study. PLoS Med. 2016 ;13(8):e1002072.
   PubMed Web of Science ®Google Scholar
• Jimenez-Corona ME, Cruz-Hervert LP, Garcia-Garcia L, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax. 2013 ;68(3):214–220.
   PubMed Web of Science ®Google Scholar
• Lee PH, Fu H, Lee MR, et al. Tuberculosis and diabetes in low and moderate tuberculosis incidence countries. Int J Tuberc Lung Dis. 2018 ;22(1):7–16.
   PubMed Web of Science ®Google Scholar
• Leung CC, Yew WW, Mok TYW, et al. Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis. Respirology. 2017;22(6):1225–1232.
   PubMed Web of Science ®Google Scholar
• van Crevel R, Koesoemadinata R, Hill PC, et al. Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis. 2018 ;22(12):1404–1410.
   PubMed Web of Science ®Google Scholar
• Lee MY, Kim YJ, Lee HJ, et al. Mean platelet volume in Mycobacterium tuberculosis infection. Biomed Res Int. 2016; 2016:7508763.
   PubMed Web of Science ®Google Scholar
• Fox KA, Kirwan DE, Whittington AM, et al. Platelets regulate pulmonary inflammation and tissue destruction in tuberculosis. Am J Respir Crit Care Med. 2018;198(2):245–255.
   PubMed Web of Science ®Google Scholar
• Vera M, Kroesen MI, Gröschel N, et al. Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: a systematic review. Front Immunol. 2017;8:772.
   PubMed Web of Science ®Google Scholar
• Hinz C, Aldrovandi M, Uhlson C, et al. Human platelets utilize cycloxygenase-1 to generate dioxolane A3, a neutrophil-activating eicosanoid. J Biol Chem. 2016;291(26):13448–13464.
   PubMed Web of Science ®Google Scholar
• Schrottmaier WC, Kral JB, Badrnya S, et al. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes. Thromb Haemost. 2015;114(3):478–489.
   PubMed Web of Science ®Google Scholar
• Kroesen VM, Rodriguez-Martinez P, Garcia E, et al. A beneficial effect of low-dose aspirin in a murine model of active tuberculosis. Front Immunol. 2018;9:798.
   PubMed Web of Science ®Google Scholar
• Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.
   PubMed Web of Science ®Google Scholar
• Cheng J, Zhang H, Zhao YL, et al. Mutual impact of diabetes mellitus and tuberculosis in China. Biomed Environ Sci. 2017;30(5):384–389.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Bai KJ, Lin HH, et al. The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis. PLoS One. 2015;10(3):e0121698.
   PubMed Web of Science ®Google Scholar
• Morsy AM, Zaher HH, Hassan MH, et al. Predictors of treatment failure among tuberculosis patients under DOTS strategy in Egypt. East Mediterr Health J. 2003;9(4):689–701.
   PubMedGoogle Scholar
• Lee MR, Lee MC, Chang CH, et al. Use of antiplatelet agents and survival of tuberculosis patients: a population-based cohort study. JCM. 2019;8(7):923.
   Google Scholar
• Palaci M, Dietze R, Hadad DJ, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol. 2007;45(12):4064–4066.
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033–2038.
   PubMed Web of Science ®Google Scholar
• Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci. 2010;293(1-2):12–17.
   PubMed Web of Science ®Google Scholar
• Mai NT, Dobbs N, Phu NH, et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. Elife. 2018;7:e33478.
   PubMed Web of Science ®Google Scholar
• Byrne ST, Denkin SM, Zhang Y. Aspirin antagonism in isoniazid treatment of tuberculosis in mice. Antimicrob Agents Chemother. 2007;51(2):794–795.
   PubMed Web of Science ®Google Scholar
• Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemost. 2010;8(8):1820–1827.
   PubMed Web of Science ®Google Scholar